COLL
Collegium Pharmaceutical Inc
23.00$
+1.2%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 88.3% | 99.1% | 97.9% | 98.5% | 81.6% | 83.5% | 43.2% | 45.6% | 35.8% | 47.0% | 29.0% | 41.7% | |
| 32.1% | 97.9% | 94.6% | 87.6% | 50.3% | 55.5% | 27.0% | 26.9% | 14.8% | 20.9% | 4.2% | 15.2% | |
| 32.1% | 97.9% | 94.6% | 87.6% | 50.3% | 55.5% | 27.0% | 26.9% | 14.8% | 27.2% | 9.8% | 24.5% | |
| 45.9% | – | 1.3% | 7.4% | 26.8% | 23.8% | 12.9% | 15.3% | 15.6% | 15.7% | 13.7% | 12.8% | |
| 25.9% | 0.0% | 0.8% | 1.3% | 2.7% | 3.1% | 2.4% | 2.5% | 4.0% | 2.8% | 2.1% | 2.5% | |
| 10.1% | 0.8% | 0.6% | 1.3% | 3.2% | 6.8% | 2.9% | 2.8% | 1.7% | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | – | – | – | 0.0% | 11.4% | 11.7% | 9.8% | 8.8% | |
| 41.3% | 0.0% | 1.3% | 0.0% | 15.2% | 9.6% | 52.2% | 38.8% | 48.3% | 36.9% | 53.6% | 40.4% | |
| 340.5% | 12.9% | 16.7% | 23.2% | 68.6% | 71.5% | 71.1% | 70.7% | 83.4% | 82.9% | 86.2% | 81.8% | |
| 204.7% | 5.9% | 14.2% | 23.2% | 64.4% | 65.9% | 37.2% | 40.4% | 36.9% | 40.1% | 30.6% | 26.6% | |
| 121.7% | 2.7% | 1.6% | 1.1% | 0.6% | 1.5% | 7.5% | 7.1% | 13.9% | 16.1% | 4.0% | 1.8% | |
| 43.4% | 5.9% | 11.1% | 4.2% | 4.2% | 2.0% | 1.6% | 0.6% | 0.3% | 0.8% | 0.2% | 0.6% | |
| 133.9% | 4.2% | 0.9% | 0.0% | 3.4% | 2.5% | 32.6% | 29.1% | 45.9% | 42.3% | 47.4% | 47.1% | |
| -240.5% | 87.1% | 83.3% | 76.8% | 31.4% | 28.5% | 28.9% | 29.3% | 16.6% | 17.1% | 13.8% | 18.2% | |
| -1,999.1% | -132.0% | -137.8% | -219.9% | -115.8% | -117.5% | -51.7% | -37.0% | -24.0% | -20.4% | -9.9% | -6.1% | |
| 146.8% | 13.9% | 15.0% | 22.3% | 11.3% | 10.9% | 5.5% | 5.9% | 2.9% | 3.7% | 2.4% | 2.4% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.